New Factor 8 Protocol Being Tested

No one likes to bleed. For a hemophiliac, a cut can be life threatening. Standard protocol is to treat them for life with a medicine called Factor 8, which helps blood clot. In some cases, a patient’s body rejects Factor 8, making it ineffective.

To maximize the benefit of this life saving medication, which can cost more than one million Saudi Riyals per patient annually, the JHAH Oncology Institute is testing a new protocol for such cases. “For a short period of time, we give a patient high doses of Factor 8,” said Dr. Mohammed AlHabib, Consultant Pharmacist. “The goal is for the body to learn to accept Factor 8 so the patient’s blood will properly clot. This will significantly enhance a patient’s quality of life.”